United Therapeutics Corporation (UTHR): Price and Financial Metrics


United Therapeutics Corporation (UTHR)

Today's Latest Price: $167.26 USD

5.15 (3.18%)

Updated Jan 14 6:55pm

Add UTHR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UTHR Stock Summary

  • UTHR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 18.6% of US stocks.
  • With a year-over-year growth in debt of -20%, UNITED THERAPEUTICS Corp's debt growth rate surpasses only 15.25% of about US stocks.
  • Over the past twelve months, UTHR has reported earnings growth of -703.98%, putting it ahead of merely 2.84% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to UNITED THERAPEUTICS Corp, a group of peers worth examining would be CERS, ACAD, EXK, GNTX, and AAOI.
  • Visit UTHR's SEC page to see the company's official filings. To visit the company's web site, go to www.unither.com.

UTHR Stock Price Chart Interactive Chart >

Price chart for UTHR

UTHR Price/Volume Stats

Current price $167.26 52-week high $171.17
Prev. close $162.11 52-week low $75.58
Day low $162.37 Volume 366,200
Day high $168.31 Avg. volume 436,333
50-day MA $144.25 Dividend yield N/A
200-day MA $119.89 Market Cap 7.43B

United Therapeutics Corporation (UTHR) Company Bio


United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.

UTHR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$167.26$215.28 29%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for UNITED THERAPEUTICS Corp. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 57th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 29.17%. In terms of the factors that were most noteworthy in this DCF analysis for UTHR, they are:

  • UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 34.82% of tickers in our DCF set.
  • UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 21.66. This coverage rate is greater than that of 87.38% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, UNITED THERAPEUTICS Corp experienced a tax rate of about 17% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 73.87% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%26%
1%27%
2%29%
3%30%
4%31%
5%32%

Want more companies with a valuation profile/forecast similar to that of UNITED THERAPEUTICS Corp? See JAZZ, CHE, HBIO, PRAH, and PBH.


UTHR Latest News Stream


Event/Time News Detail
Loading, please wait...

UTHR Latest Social Stream


Loading social stream, please wait...

View Full UTHR Social Stream

Latest UTHR News From Around the Web

Below are the latest news stories about UNITED THERAPEUTICS Corp that investors may wish to consider to help them evaluate UTHR as an investment opportunity.

United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.

Yahoo | January 4, 2021

Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

United Therapeutics (NASDAQ:UTHR) has had a great run on the share market with its stock up by a significant 44% over...

Yahoo | January 4, 2021

United Therapeutics Buys Priority Review Voucher for $105M

United Therapeutics Corporation has announced that it has agreed to buy a Priority Review Voucher (PRV) for $105 million, which it plans to use with an application to get a new drug approved by the U.S. Food and Drug Administration (FDA). The PRV allows United Therapeutics to receive an expedited eight-month review of the new drug application, instead of the standard twelve-month review period. United Therapeutics (UTHR) intends to apply the PRV to get approval for Tyvaso DPI, a pulmonary arterial hypertension (PAH) treatment that improves exercise ability in patients.

Daniel Plaks on TipRanks | December 28, 2020

Y-mAbs Announces Sale of Priority Review Voucher

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (“PRV”) to United Therapeutics Corporation (Nasdaq: UTHR), based on an agreed valuation of $105 million.The PRV was granted in conjunction with the approval by the U.S. Food and Drug Administration (“FDA”) of DANYELZA®, for the treatment of refractory/relapsed high-risk neuroblastoma.Under the terms of the Company’s license agreement with Memorial Sloan Kettering Cancer Center (“MSK”), Y-mAbs is entitled to reta...

Yahoo | December 28, 2020

United Therapeutics Announces Agreement To Acquire Priority Review Voucher

United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The PRV entitles the holder to designate an NDA for priority review and provides for an expedited eight-month review, instead of the standard twelve-month review period. Following the close of the transaction, United Therapeutics intends to apply the PRV to its NDA for Tyvaso DPI, expected in the first half of 2021.

Yahoo | December 28, 2020

Read More 'UTHR' Stories Here

UTHR Price Returns

1-mo 14.37%
3-mo 45.44%
6-mo 42.71%
1-year 77.69%
3-year 23.79%
5-year 25.66%
YTD 10.19%
2020 72.33%
2019 -19.12%
2018 -26.39%
2017 3.15%
2016 -8.42%

Continue Researching UTHR

Want to see what other sources are saying about UNITED THERAPEUTICS Corp's financials and stock price? Try the links below:

UNITED THERAPEUTICS Corp (UTHR) Stock Price | Nasdaq
UNITED THERAPEUTICS Corp (UTHR) Stock Quote, History and News - Yahoo Finance
UNITED THERAPEUTICS Corp (UTHR) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9048 seconds.